Adtran’s Oscilloquartz optical cesium clock outperforms in tests at leading European metrology institute
5.9.2023 15:00:00 EEST | Business Wire | Press release
Adtran today announced that one of the world’s leading metrology institutes has conducted a three-month-long evaluation of its OSA 3300-HP high-performance optical cesium atomic clock. Based in Central Europe, the national laboratory tested Adtran’s industry-first solution to establish its suitability for scientific measurement and calibration applications that require precise synchronization. The OSA 3300-HP succeeded in delivering the strict timing accuracy and long-term stability needed for metrology use cases with results far exceeding product specifications. The findings underline the value of Adtran’s Oscilloquartz optical cesium technology for a broad spectrum of industries, from astronomical research to defense operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905097567/en/
Adtran’s OSA 3300-HP has set new benchmarks for timing accuracy and long-term stability. (Photo: Business Wire)
“We’re pleased to see this validation for our OSA 3300-HP. As the market’s first commercial high-performance optical cesium atomic clock, it offers levels of performance that far exceed best-in-class magnetic cesium devices. Its unique capabilities have the potential to enhance the work of scientists and engineers in a diverse range of metrology, science, research, time scale and ground station fields, including space exploration,” said Gil Biran, GM of Oscilloquartz, Adtran. “Now that it’s achieved these successful results in some of the industry’s most thorough tests, science and research institutions across the world will be able to harness our device to bring new levels of accuracy to their work.”
Adtran’s OSA 3300-HP represents a major achievement in network synchronization. Building on Oscilloquartz’s 74-year history and the expertise of its team, the device provides a precise and ultra-stable frequency source for the most demanding and critical applications. It enables highly accurate synchronization over an extended 10-year lifetime thanks to its advanced optical cesium technology, which pumps atoms to the desired energy states more efficiently than legacy magnetic-based solutions. The OSA 3300-HP’s robust and compact design makes it suitable for multiple applications, even in ground space-constrained environments. It’s also fully compliant with the latest RoHS standards and strict EU demands.
“Assessments by this leading scientific evaluation center are recognized as among the most stringent evaluations in the world of metrology. By meeting and surpassing these rigorous standards, our OSA 3300-HP has proven its value for metrology, time-keeping institutes and scientific research. It will be the foundation for future innovation in sectors from satellite navigation to nanoscale technology,” commented Jörg Urban, AVP of EMEA business development at Oscilloquartz, Adtran. “Our optical pumping timing solutions have set a new benchmark for precision and availability. As well as having a transformative impact on metrology advancement, our technology provides the vital resilience required for PNT assurance in critical infrastructure. What’s more, it empowers communication service providers to harness robust and accurate GNSS backup to deliver valuable timing offerings with differentiated service level agreements.”
Further details including official results from the OSA 3300-HP evaluation are now available on request.
A brief summary of the findings can also be found in these slides.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905097567/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Launches Multi-Orbit Satellite Connectivity on LATAM Airbus, Embraer Fleet29.7.2026 18:30:00 EEST | Press release
SES, a leading space solutions company, was selected by LATAM Airlines to provide multi-orbit inflight connectivity service to its growing fleet of Airbus and Embraer aircraft, solidifying SES’s position as the top provider of multi-orbit broadband service in the Americas and around the world. “LATAM’s passengers will soon benefit from reliable, multi-orbit satellite connectivity that will provide the same fast and dependable internet access they enjoy at home no matter where or when they fly. SES’s partnerships with airlines like LATAM highlight how carriers throughout the Americas are leading the way when it comes to the most advanced connectivity. SES is a trusted partner that powers inflight connectivity,” said Mike DeMarco, SES President of Mobility. More than 60 Airbus (A320NEO and A321XLR) and Embraer aircraft (E195-E2) will be equipped with SES services in the coming years. LATAM will be the largest airline in the region to offer service using SES’s new electronically steered a
Carta Rearchitects Private Capital Operations with Plugins for Claude29.7.2026 17:01:00 EEST | Press release
Carta, the connected platform and AI-native ecosystem for private capital, today announces broad availability of its suite of Plugins for Claude following the initial launch in April 2026. With more than 1,500 companies and firms already using the plugins, Carta is changing the way private capital teams — from founders to CFOs — fundamentally operate, bringing fund administration, cap table management, and dealflow analytics directly into the spreadsheets, presentations, and workflows they already use every day. "For the last decade, private capital operation teams have been held back by a hidden tax: the constant, manual handoff of data between disconnected systems," said Henry Ward, Carta CEO. "Carta is eliminating that broken loop entirely by embedding intelligence directly into the tools teams already use. We are not waiting for an AI-native future for private capital — it is running on Carta today." Carta didn't just give Claude a pipe to its data. Carta built its private-capital
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29.7.2026 16:00:00 EEST | Press release
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant milestone in advancing treatment for tricuspid regurgitation (TR). The prospective, global, multicenter, randomized (1:1) controlled study is designed to evaluate the safety and effectiveness of the TriNova TTVR system in patients with severe or greater tricuspid regurgitation who are suitable for valve replacement. The study will be conducted in the US and Europe with up to 70 sites participating. The first patient was enrolled at the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, and tre
Grid Dynamics Accelerates Enterprise AI-Native Transformation With Workforce Certification and GAIN Platforms Rollout29.7.2026 16:00:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a leading provider of technology consulting, platform and product engineering, and AI-driven digital transformation services, today announced significant momentum in the adoption of its enterprise agentic AI solutions. Organizations across retail, financial services, manufacturing, CPG, and logistics industries are increasingly deploying Grid Dynamics’ agentic AI-native platforms and Forward Deployed Engineering (FDE)-led services to accelerate software delivery, improve operational efficiency, and transform business processes at scale. Grid Dynamics is widely recognized for its enterprise AI expertise and delivery capabilities across Fortune 1000 organizations. Grid Dynamics has partnership agreements with Anthropic and OpenAI to accelerate the adoption of these platforms within enterprises. By the end of October 2026, Grid Dynamics plans to have 90% of its engineers trained and certified on these platforms. Built to suppo
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29.7.2026 16:00:00 EEST | Press release
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant milestone in advancing treatment for tricuspid regurgitation (TR). The prospective, global, multicenter, randomized (1:1) controlled study is designed to evaluate the safety and effectiveness of the TriNova TTVR system in patients with severe or greater tricuspid regurgitation who are suitable for valve replacement. The study will be conducted in the US and Europe with up to 70 sites participating. The first patient was enrolled at the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, and tre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
